AFT Pharmaceuticals Limited (NZE:AFT)
New Zealand · Delayed Price · Currency is NZD | Market Cap | 471.94M +36.0% |
| Revenue (ttm) | 254.71M +22.4% |
| Net Income | 14.73M +23.1% |
| EPS | 0.14 +27.3% |
| Shares Out | 104.87M |
| PE Ratio | 32.14 |
| Forward PE | 23.96 |
| Dividend | 0.03 (0.56%) |
| Ex-Dividend Date | Jun 18, 2026 |
| Volume | 26,040 |
| Open | 4.500 |
| Previous Close | 4.500 |
| Day's Range | 4.490 - 4.520 |
| 52-Week Range | 3.160 - 4.850 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 4.85 (+7.78%) |
| Est. Earnings | Nov 19, 2026 |
About AFT Pharmaceuticals
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA ... [Read more]
Financial Performance
In fiscal year 2026, AFT Pharmaceuticals's revenue was 254.71 million, an increase of 22.44% compared to the previous year's 208.02 million. Earnings were 14.73 million, an increase of 23.14%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AFT stock is "Buy." The 12-month stock price target is $4.85, which is an increase of 7.78% from the latest price.
News
Hyloris Partner AFT Signs Exclusive Japan Deal For Maxigesic IV
(RTTNews) - Hyloris Pharmaceuticals SA (HYL.BR) announced that its partner AFT Pharmaceuticals Ltd. (AFT.NZ) has entered into an exclusive agreement with Mikasa Seiyaku Co Ltd. for the commercializati...
AFT Pharmaceuticals Transcript: AGM 2026
Record revenue and profit growth were reported, with expanded global reach and increased dividend. Strategic focus remains on R&D, international expansion, and operational efficiency. Board transitions and strong governance were highlighted, with all resolutions passed by overwhelming majority.
AFT Pharmaceuticals Slides: FY 2026
AFT Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on July 30, 2026.
AFT Pharmaceuticals Earnings release: Trading update
AFT Pharmaceuticals released its earnings on July 6, 2026, summarizing the period's financial results.
AFT Pharmaceuticals Earnings Call Transcript: H2 2026
Revenue grew 22% to NZD 254.7 million with record operating profit and dividend, driven by strong growth in Australia, New Zealand, and Asia. Expansion and R&D investment continue, with a sales target of NZD 300 million and operating profit guidance of NZD 28–32 million.
AFT Pharmaceuticals Slides: H2 2026
AFT Pharmaceuticals has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 20, 2026.
AFT Pharmaceuticals Earnings release: H2 2026
AFT Pharmaceuticals released its H2 2026 earnings on May 20, 2026, summarizing the period's financial results.
AFT Pharmaceuticals Annual report: H2 2026
AFT Pharmaceuticals has published its H2 2026 annual report on May 20, 2026.
AFT Pharmaceuticals Earnings Call Transcript: H1 2026
Sales grew 33% year-over-year to nearly NZD 115 million, with strong gains in Australia, Asia, and international markets. Operating profit rebounded to NZD 4.7 million, and guidance for EBIT and revenue was maintained despite higher R&D and ERP costs.
AFT Pharmaceuticals Quarterly report: H1 2026
AFT Pharmaceuticals has published its H1 2026 quarterly earnings report on November 19, 2025.
AFT Pharmaceuticals Slides: H1 2026
AFT Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 19, 2025.
AFT Pharmaceuticals Earnings release: H1 2026
AFT Pharmaceuticals released its H1 2026 earnings on November 19, 2025, summarizing the period's financial results.